Oxaliplatin downregulates the expression of the inhibitory protein programmed death receptor‐ligand 2 (PD‐L2) on DC and tumor cells, resulting in more efficient tumor‐specific T‐cell responses.9 In contrast, oxaliplatin increases the expression of PD‐L1 on plasmacytoid DCs and weakens their immunogenicity.10 Despite the interesting immunoregulatory capacity of oxaliplatin, previous studies have limited their focus to immune effector cells, particularly DCs.9, 10 Herein, we focused on another myeloid lineage cell, myeloid‐derived suppressor cells (MDSCs). Here, CD274 is linked to neoplasm.